Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. For over 25 years, our innovative tools have been used to obtain, analyze, and utilize cells. 2,000 employees in 15 international locations are dedicated to helping researchers and clinicians make a greater impact on science and health
Cisbio develops and markets products and technologies used for in vitro diagnostics and drug discovery. With its proprietary technology, HTRF®, the company is a leader in homogeneous fluorescence detection methods and offers first class assays and services for drug discovery researchers. Cisbio operates globally and enables basic research and drug discovery projects to move faster, with the support of its scientific experts.Drop by our booth, discover Cisbio's assays for a broad range of therapeutic targets and readouts, and see how we make daily science easier.
Ultivue provides translational researchers and scientists with a simple, fast, fully optimized and biologically relevant set of next gen multiplex IHC panels. Ultivue’s InSituPlex® technology eliminates the need for assay development and enables scientists to unmask and analyze the true biological context of tissue samples. Through increased sensitivity and specificity, Ultivue UltiMapper™ kits provide robust and reproducible results right out of the box with seamless integration into existing workflows and equipment.
Sponsors & Exhibitors
Eurogentec, part of Kaneka Corporation, is a leading supplier of specialty products and custom services. Through its three inter-related business units (Life Science Research, Diagnostic services and GMP BioManufacturing), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the manufacturing of a commercial biologic.
At GE Healthcare Life Sciences, we accelerate precision medicine by helping researchers, pharmaceutical companies and clinicians discover and make new medicines and therapies. We provide expertise, technology and services for a wide range of areas within the life sciences industry, including the manufacture of contrast agents for diagnostic imaging, basic research of cells and proteins and technologies that enable large-scale manufacturing of vaccines, biologics and cell therapy. The emergence of cell therapy as a frontline treatment for challenging diseases, including cancer, is rapidly changing the healthcare landscape. Our Cell Therapy business provides the tools, technology and processes to enable customers from pharmaceutical manufacturing as part of our Cell Processing segment, to clinicians and technicians in our Cell Banking and Point of Care business segments. We are investing in the field for the long-term, and partnering with pharma, biotech and clinical researchers. GE brings expertise in quality, global distribution, research and development and regulatory that will transform cell therapy from small-scale treatment to a globally-accessible personalized medicine.
Lonza provides the pharma market with the tools that life-science researchers use to develop and test therapeutics, beginning with basic research stages on to the final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research to quality control tests and software that ensures product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies. The company delivers physiologically relevant cell biology solutions and complete solutions for rapid microbiology.
Almac Sciences, an established, leading contract development and manufacturing organisation, provides specialist services supporting oncology research. In particular, our peptide manufacturing team has experience in the manufacture of many classes of peptides which are useful as tools in cancer research. In addition, we have a unique blend of experience in manufacturing multi-component peptide vaccines, including our NeoPeptide™ offering for individualized treatments.
Source BioScience has over 15 years’ experience of delivering genomics projects for BioPharm, Biotech, and Academic clients to GCP when required. Our portfolio of Genomics Services includes Sanger Sequencing(overnight service), next generation sequencing, microarray analysis, genotyping, DNA/RNA extraction and bioinformatics.
From project planning to delivery of data Source BioScience has become a trusted partner to our clients, find out how we can help you by talking to our Technical representatives at booth EX-17.
Marks & Clerk are committed to providing exceptional intellectual property advice around the world, helping you to navigate the complexities of IP, patents, trade marks and design protection. Innovation is the life-blood of business and it’s vital that you do not overlook the need to protect your intellectual property. From the capture of an idea, to the enforcement or defence of rights in disputes Marks & Clerk is your expert partner to ensure your IP is protected and fully exploited. Today’s local is tomorrow’s global – and with our diverse team of practitioners, you’re always supported by a network of experts.
PromoCell is a premier manufacturer of cell culture products. We are known for our broad range of human primary cells, stem cells and blood cells, optimized cell culture media, and a comprehensive line of cell biology research products
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens. The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors. VAXIMM completed a Phase I/II trial of VXM01 in advanced pancreatic cancer. Clinical trials are completed or ongoing in metastatic colorectal cancer and in recurrent glioblastoma (brain cancer). Recently a combination study with VXM01 and Avelumab in recurrent GBM in collaboration with Merck and Pfizer has been started. The Company has several additional product candidates at various stages of preclinical development. These candidates can be developed as standalone therapies or in combination with other immunotherapies, including VXM01. VAXIMM’s investors include BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland with a wholly owned subsidiary, VAXIMM GmbH (Mannheim, Germany), from where the Company’s development activities are orchestrated, and a laboratory in Regensburg, Germany.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.
iOnctura is a biopharmaceutical company developing a pipeline of next-generation molecules for the treatment of cancer and fibrosis. With programs harnessing both immune-mediated and direct anti-tumor activity iOnctura aims to deliver superior clinical efficacy in oncology and build on complementary mechanisms between cancer and fibrosis. iOnctura will be the first company to clinically evaluate single-agent immuno-modulatory effects of a specific Pi3Kd inhibitor and an Autotaxin inhibitor in solid tumors.
NEBION provides scientists and biomedical researchers with GENEVESTIGATOR®, the premier application for the meta-analysis of public and private gene expression data. Users particularly appreciate the high quality of curated data in combination with the intuitive data mining tools, which they use for the identification and characterization of novel biomarkers and drug targets, prediction of side effects and drug repurposing. Besides the constant expansion and development of GENEVESTIGATOR®, NEBION offers transcriptomics data curation and analysis services.
TransCure bioServices is the only CRO specialized in full human immune system mouse disease models for Cancer, Infectious, Inflammation and Vaccines.
Customers access these full services (protocol design, raw data collection, analysis, reports) in our BSL-2 and BSL-3 animal and laboratory technology (flow cytometry, cell biology) facilities on a very attractive fee-for-service basis.
Highest needs for large pharmaceutical and biotechnology companies as well as academic laboratories which can profile new preclinical/clinical drug candidates (small molecules, peptides, biologics, mAb, vaccines) targeting immuno-related diseases such as inflammation, cancer, or infectious diseases. TransCure bioServices is your one stop shop for in vivo pharmacology preclinical expertise.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates and accelerate drug development programs. CrownBio also provides preclinical immunotherapy research platforms supporting the successful transition of immunotherapeutics from the lab into the clinic.
LIfT Biosciences is a Biotech bringing to market a 1st in classImmuno-Oncology Cell Therapy called N-LIfT that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT (Neutrophil Only Leukocyte Infusion Therapy) builds on 18 years of ground breaking research into innate cancer immunity. Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for curing all solid tumours.
Myriad RBM, Inc is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.